Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on SAB Biotherapeutics. The associated price target remains the same with $9.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Emily Bodnar’s rating is based on the promising developments in SAB Biotherapeutics’ clinical trials, particularly the Phase 2b SAFEGUARD study, which is designed as a pivotal trial for FDA approval. The trial’s design and endpoints have received alignment from the FDA, suggesting a clear path toward regulatory approval. The company’s decision to forego an interim analysis in favor of seeking full approval indicates confidence in the trial’s potential outcomes.
Additionally, the Phase 1 data for SAB-142 has shown promising results, including sustained CD4+ T cell exhaustion and differentiation into memory T cells, which are crucial for treating T1D. The safety profile of SAB-142 appears favorable compared to existing treatments, with no cases of serum sickness or anti-drug antibodies, which are common with other therapies. These factors combined suggest that SAB Biotherapeutics is well-positioned for future success, justifying the Buy rating.